Danh mục tài liệu

A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors

Số trang: 13      Loại file: pdf      Dung lượng: 802.99 KB      Lượt xem: 9      Lượt tải: 0    
Xem trước 2 trang đầu tiên của tài liệu này:

Thông tin tài liệu:

The RAS/RAF/MEK/ERK pathway is constitutively activated in many cancers. Selumetinib (AZD6244, ARRY-142886) is an oral, potent and highly selective, allosteric MEK1/2 inhibitor with a short half-life that has shown clinical activity as monotherapy in phase I and II studies of advanced cancer.
Nội dung trích xuất từ tài liệu:
A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors